Eton Pharmaceuticals (NASDAQ:ETON) Price Target Raised to $33.00 at HC Wainwright

Eton Pharmaceuticals (NASDAQ:ETON) had its price objective upped by HC Wainwright from $17.00 to $33.00 in a research report released on Thursday, MarketBeat.com reports. HC Wainwright currently has a buy rating on the stock.

Other equities research analysts also recently issued reports about the company. B. Riley began coverage on Eton Pharmaceuticals in a research note on Friday, January 10th. They set a “buy” rating and a $21.00 price target for the company. Craig Hallum boosted their target price on shares of Eton Pharmaceuticals from $15.00 to $18.00 and gave the company a “buy” rating in a research report on Wednesday, January 8th.

Eton Pharmaceuticals Stock Up 10.8 %

Shares of NASDAQ ETON opened at $16.24 on Thursday. The firm’s 50-day moving average price is $12.70 and its 200-day moving average price is $8.12. Eton Pharmaceuticals has a 52-week low of $3.03 and a 52-week high of $16.62. The company has a market cap of $423.05 million, a PE ratio of -73.82 and a beta of 1.38.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Parkman Healthcare Partners LLC raised its holdings in Eton Pharmaceuticals by 2.8% during the 3rd quarter. Parkman Healthcare Partners LLC now owns 260,226 shares of the company’s stock valued at $1,561,000 after buying an additional 7,029 shares during the period. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Eton Pharmaceuticals in the third quarter valued at $54,000. Jane Street Group LLC bought a new stake in shares of Eton Pharmaceuticals in the 3rd quarter worth about $90,000. Baader Bank Aktiengesellschaft purchased a new position in shares of Eton Pharmaceuticals during the 4th quarter worth about $373,000. Finally, Connor Clark & Lunn Investment Management Ltd. boosted its stake in shares of Eton Pharmaceuticals by 86.6% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 65,014 shares of the company’s stock worth $390,000 after purchasing an additional 30,167 shares during the period. Institutional investors own 27.86% of the company’s stock.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.